Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposing HIV Antivirals in Adults With Long Covid
NCT06511063Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-acute sequelae of SARS-CoV-2 infection (PASC) comparing Truvada, Selzentry and Placebo (3 arms). Primary endpoint: EuroQol 5-Dimension 5-Level Visual Analogue Scale at Day 180. Started Oct 2024; status: recruiting.
02
Drugs
emtricitabine + tenofovir disoproxilmaraviroc
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06511063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511063.